国际口腔医学杂志 ›› 2024, Vol. 51 ›› Issue (4): 392-400.doi: 10.7518/gjkq.2024078
• 牙周病学专栏 • 上一篇
Meiyao Qi(),Xingying Qi,Xinyi Zhou,Zhen Tan,Quan Yuan(
)
摘要:
目的 通过体内外实验探索大麻二酚(CBD)联合米诺环素(MINO)对小鼠实验性牙周炎的治疗作用。 方法 丝线结扎法建立小鼠牙周炎模型,口腔局部分别给予CBD、MINO及二者联用, 通过定量反转录聚合酶链反应(qRT-PCR)检测牙周炎小鼠用药后外周血炎症因子变化,Micro CT、免疫印迹(WB)及苏木精-伊红(HE)染色分析局部位点炎症改善情况;牙龈卟啉单胞菌抑菌实验检测联用药物体外抗菌性能;体外诱导巨噬细胞及牙龈成纤维细胞炎症,通过qRT-PCR检测炎症相关mRNA表达,划痕实验探索药物对细胞迁移的影响,并通过酶联免疫吸附(ELISA)测定探究药物对于胶原生成的作用。 结果 联用CBD与MINO后,与单独用药相比,小鼠全身炎症指标下降,局部附着丧失减轻、组织炎症水平降低、牙周软硬组织破坏得到改善;体外抑菌实验结果表明联用药物表现出良好的抗菌性能;体外细胞实验证明联用药物降低巨噬细胞多种炎症因子的表达水平,促进炎症状态下人牙龈成纤维细胞增殖、迁移,提升胶原形成功能。 结论 相较单一用药方式法,局部应用CBD联合MINO对小鼠实验性牙周炎有着显著疗效。
中图分类号:
1 | Kwon T, Lamster IB, Levin L. Current concepts in the management of periodontitis[J]. Int Dent J, 2021, 71(6): 462-476. |
2 | Fischer RG, Lira Junior R, Retamal-Valdes B, et al. Periodontal disease and its impact on general health in Latin America. Section V: treatment of periodontitis[J]. Braz Oral Res, 2020, 34(supp1 1): e026. |
3 | Simpson TC, Clarkson JE, Worthington HV, et al. Treatment of periodontitis for glycaemic control in people with diabetes mellitus[J]. Cochrane Database Syst Rev, 2022, 4(4): CD004714. |
4 | Lin HB, Chen HS, Zhao XT, et al. Advances of exosomes in periodontitis treatment[J]. J Transl Med, 2022, 20(1): 279. |
5 | GBD Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1789-1858. |
6 | 台保军. 中国居民口腔健康状况及防控策略:第四次全国口腔健康流行病学调查结果解读[C]//第十三次全国老年口腔医学学术年会论文汇编. 武汉, 2018: 16-17. |
Tai BJ. Oral health status of Chinese residents and prevention and control strategies: interpretation of the results of the fourth national oral health epide-miological survey[C]//The 13th National Annual Conference of Geriatric Stomatology. Wuhan, 2018: 16-17. | |
7 | Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation[J]. Nat Rev Immunol, 2015, 15(1): 30-44. |
8 | Hajishengallis G, Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities[J]. Nat Rev Immunol, 2021, 21(7): 426-440. |
9 | Genco RJ, Sanz M. Clinical and public health implications of periodontal and systemic diseases: an overview[J]. Periodontol 2000, 2020, 83(1): 7-13. |
10 | Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabi-diol: state of the art and new challenges for therapeutic applications[J]. Pharmacol Ther, 2017, 175: 133-150. |
11 | Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes[J]. J Clin Invest, 2014, 124(9): 3713-3724. |
12 | Wroński A, Jarocka-Karpowicz I, Stasiewicz A, et al. Phytocannabinoids in the pharmacotherapy of psoriasis[J]. Molecules, 2023, 28(3): 1192. |
13 | Ramer R, Hinz B. Cannabinoid compounds as a pharmacotherapeutic option for the treatment of non-cancer skin diseases[J]. Cells, 2022, 11(24): 4102. |
14 | Casares L, García V, Garrido-Rodríguez M, et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1[J]. Redox Biol, 2020, 28: 101321. |
15 | Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis[J]. Proc Natl Acad Sci U S A, 2000, 97(17): 9561-9566. |
16 | Qi X, Lin W, Wu Y, et al. CBD promotes oral ulcer healing via inhibiting CMPK2-mediated inflammasome[J]. J Dent Res, 2022, 101(2): 206-215. |
17 | Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics[J]. Curr Mol Pharmacol, 2021, 14(6): 1046-1065. |
18 | Asadi A, Abdi M, Kouhsari E, et al. Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: back to the future[J]. J Glob Antimicrob Resist, 2020, 22: 161-174. |
19 | Afshari AR, Mollazadeh H, Sahebkar A. Minocycline in treating glioblastoma multiforme: far beyond a conventional antibiotic[J]. J Oncol, 2020, 2020: 8659802. |
20 | Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis[J]. Lancet Neurol, 2020, 19(4): 336-347. |
21 | Dogaru IA, Puiu MG, Manea M, et al. Current perspectives on pharmacological and non-pharmacolo-gical interventions for the inflammatory mechanism of unipolar depression[J]. Brain Sci, 2022, 12(10): 1403. |
22 | Morris G, Walker AJ, Berk M, et al. Cell death pathways: a novel therapeutic approach for neuroscientists[J]. Mol Neurobiol, 2018, 55(7): 5767-5786. |
23 | Shankar C, Nabarro LEB, Anandan S, et al. Minocycline and tigecycline: what is their role in the treatment of carbapenem-resistant gram-negative orga-nisms[J]. Microb Drug Resist, 2017, 23(4): 437-446. |
24 | Franco V, Gershkovich P, Perucca E, et al. The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations[J]. Clin Pharmacokinet, 2020, 59(12): 1493-1500. |
25 | Kim EK, Jang SH, Choi YH, et al. Effect of an oral hygienic care program for stroke patients in the intensive care unit[J]. Yonsei Med J, 2014, 55(1): 240-246. |
26 | de Molon RS, Mascarenhas VI, de Avila ED, et al. Long-term evaluation of oral gavage with periodontopathogens or ligature induction of experimental periodontal disease in mice[J]. Clin Oral Investig, 2016, 20(6): 1203-1216. |
27 | Polak D, Wilensky A, Shapira L, et al. Mouse model of experimental periodontitis induced by Porphyromonas gingivalis/Fusobacterium nucleatum infection: bone loss and host response[J]. J Clin Perio-dontol, 2009, 36(5): 406-410. |
28 | Chen WP, Chang SH, Tang CY, et al. Composition analysis and feature selection of the oral microbiota associated with periodontal disease[J]. Biomed Res Int, 2018, 2018: 3130607. |
29 | Teles F, Collman RG, Mominkhan D, et al. Viruses, periodontitis, and comorbidities[J]. Periodontol 2000, 2022, 89(1): 190-206. |
30 | Xu WZ, Zhou W, Wang HZ, et al. Roles of Porphyromonas gingivalis and its virulence factors in pe-riodontitis[J]. Adv Protein Chem Struct Biol, 2020, 120: 45-84. |
31 | Herrera D, Sanz M, Kebschull M, et al. Treatment of stage Ⅳ periodontitis: the EFP S3 level clinical practice guideline[J]. J Clin Periodontol, 2022, 49(): 4-71. |
32 | West N, Chapple I, Claydon N, et al. BSP implementation of European S3-level evidence-based treatment guidelines for stage Ⅰ-Ⅲ periodontitis in UK clinical practice[J]. J Dent, 2021, 106: 103562. |
33 | Oh TJ, Yu SH. Evidence-based clinical practice guideline for treatment of stage IIII periodontitis[J]. J Evid Based Dent Pract, 2021, 21(4): 101638. |
34 | Stahl V, Vasudevan K. Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: a preliminary observation[J]. Cureus, 2020, 12(1): e6809. |
35 | Fatima T, Khurshid Z, Rehman A, et al. Gingival crevicular fluid (GCF): a diagnostic tool for the detection of periodontal health and diseases[J]. Molecules, 2021, 26(5): 1208. |
36 | Surlin P, Gheorghe DN, Popescu DM, et al. Interleukin-1α and-1β assessment in the gingival crevicular fluid of periodontal patients with chronic hepatitis C[J]. Exp Ther Med, 2020, 20(3): 2381-2386. |
37 | Preshaw PM, Taylor JJ, Jaedicke KM, et al. Treatment of periodontitis reduces systemic inflammation in type 2 diabetes[J]. J Clin Periodontol, 2020, 47(6): 737-746. |
38 | Li C, Yu R, Ding YM. Association between Porphyromonas Gingivalis and systemic diseases: focus on T cells-mediated adaptive immunity[J]. Front Cell Infect Microbiol, 2022, 12: 1026457. |
39 | Yang RQ, Guo SJ, Xiao SM, et al. Enhanced wound healing and osteogenic potential of photodynamic therapy on human gingival fibroblasts[J]. Photodiagnosis Photodyn Ther, 2020, 32: 101967. |
40 | Amberg R, Elad A, Rothamel D, et al. Design of a migration assay for human gingival fibroblasts on biodegradable magnesium surfaces[J]. Acta Biomater, 2018, 79: 158-167. |
[1] | 杨再目,曹沛,刘振华,栾庆先. 血浆无细胞线粒体外线粒体DNA与牙周炎临床指标的相关性研究[J]. 国际口腔医学杂志, 2024, 51(3): 288-295. |
[2] | 马瑜鸿,赵蕾. 微创非手术牙周治疗技术的临床研究进展[J]. 国际口腔医学杂志, 2024, 51(2): 227-232. |
[3] | 傅豫, 何薇, 黄兰. 铁死亡在口腔疾病中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 36-44. |
[4] | 罗晓洁,王德续,陈晓涛. 基于生物信息学分析铁死亡调控基因与牙周炎的关系[J]. 国际口腔医学杂志, 2023, 50(6): 661-668. |
[5] | 黄元鸿,彭显,周学东. 骨碎补在治疗口腔骨相关疾病的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 679-685. |
[6] | 王仁义,赵呈智,潘剑. 拔牙围手术期预防性使用抗生素对术后并发症影响的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 558-565. |
[7] | 龚美灵,程兴群,吴红崑. 牙周炎与帕金森病相关性的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 587-593. |
[8] | 孙佳,韩烨,侯建霞. 白细胞介素-6-铁调素信号轴调控牙周炎相关性贫血致病机制的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 329-334. |
[9] | 刘体倩,梁星,刘蔚晴,李晓虹,朱睿. 咬合创伤在牙周炎发生发展中的作用及机制的研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 19-24. |
[10] | 李琼,于维先. 白藜芦醇治疗牙周炎及其生物利用度的研究进展[J]. 国际口腔医学杂志, 2023, 50(1): 25-31. |
[11] | 黄伟琨,徐秋艳,周婷. 黄芩苷抑制脂多糖促巨噬细胞氧化应激损伤作用的研究[J]. 国际口腔医学杂志, 2022, 49(5): 521-528. |
[12] | 周剑鹏,谢旭东,赵蕾,王骏. 辅助性T细胞17及白细胞介素17在牙周炎中的作用及机制的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 586-592. |
[13] | 陈荟宇,白明茹,叶玲. 信号素3A与口腔常见病关系的研究进展[J]. 国际口腔医学杂志, 2022, 49(5): 593-599. |
[14] | 周佳佳,赵蕾,徐欣. 牙周炎相关基因多态性的研究进展[J]. 国际口腔医学杂志, 2022, 49(4): 432-440. |
[15] | 马玉,左玉,张鑫. 光动力疗法辅助治疗牙周炎治疗效果的Meta分析[J]. 国际口腔医学杂志, 2022, 49(3): 305-316. |
|